Last reviewed · How we verify
NCT01707537: OCV
Phase I Study to Determine the Safety and Immunogenicity of Euvichol(Oral Cholera Prevention Vaccine)in Healthy Adult Men ; Open, Non-comparative Clinical Trial
Phase 1 trial testing Euvichol in Prevention Harmful Effects in 20 participants. Completed in 1 February 2013.
1 February 2013
Quick facts
| Lead sponsor | EuBiologics Co.,Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 1 September 2012 |
| Primary completion | 1 February 2013 |
| Estimated completion | 1 February 2013 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Euvichol — full drug profile →
Conditions studied
- Prevention Harmful Effects — all drugs for Prevention Harmful Effects →
Sponsor
EuBiologics Co.,Ltd — full company profile →
Who can join
20 and older, male only, with Prevention Harmful Effects. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Safety(proportion of subjects with adverse events)
Time frame: From the date of the first orally administered for 4 weeks after the second dose
The proportion of all adverse event and serious adverse event which were occured during the entire study period is analyzed and casuality between severity and investigational product is presented. Check the vital signs, physical examination and clinical laboratory tests
Sponsor's own description
To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.
Baik YO, Choi SK, Kim JW, Yang JS, et al · · 2014 · cited 23× · PMID 24753695 · DOI 10.3346/jkms.2014.29.4.494
Verify or expand the search:
- PubMed search for NCT01707537
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other EuBiologics Co.,Ltd trials
Trials by the same sponsor.
- NCT06409494 — Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years · Phase 1 · active not recruiting
- NCT06216093 — Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 8 · Phase 1 · active not recruiting
- NCT05739292 — Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Year · Phase 1 · completed
- NCT05572879 — A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults · Phase 3 · completed
- NCT05603052 — A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01707537 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by EuBiologics Co.,Ltd
- Last refreshed: 18 February 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01707537.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing